Activity Provided by the American Epilepsy Society in conjunction with Dartmouth Health and the Managing Epilepsy Well Network.
Release Date: 9.29.2023
Expiration Date: 9.29.2026This course, developed for the non-epilepsy specialist healthcare provider, includes content that focuses on living with epilepsy.
About 3.4 million people in the United States live with active epilepsy. Epilepsy is a complex spectrum of disorders characterized by recurrent seizures. Seizures are not the only challenge that people with epilepsy face, as they are often confronted with complex medication regimens, lifestyle adjustments, co-morbid disease, disability, under- or unemployment, limited access to transportation, and stigma. This session will focus on some of the everyday challenges people with epilepsy and their caregivers face, including cognitive difficulties for people with epilepsy, self-management practices and programs that address those cognitive difficulties, models of care for pregnant people with epilepsy, and the impact on caregivers of people with epilepsy.
Some content was originally presented at the American Epilepsy Society Annual Meeting in December 2022.
This course is supported by the Centers for Disease Control (CDC) and Prevention of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $1,500,000 with 100 percent funded by CDC/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by CDC/HHS, or the U.S. Government.Learning Objectives
- Describe common challenges impacting people living with epilepsy across the lifespan
- Identify cognitive and psychiatric comorbidities which are common in epilepsy
- Discuss support available through self-management programs and community organizations
FacultyKristen Seaborg, MDUniversity of Wisconsin
Janelle Wagner, PhD, FAESMedical University of South Carolina
Barbara Jobst, MD, Dr. Med, FAES, FAAN*Geisel School of Medicine at Dartmouth Health
Contract Research: Neuropace, Inc.
Sarita Maturu, DOThe Ohio State University Wexner Medical Center
Naymee Velez Ruiz, MD, FAESUniversity of Miami
Patrick Kwan, MD, PhD*Monash Institute of Medical Engineering
Grant: Eisai, Inc., UCBGita Gupta, MD, MSUniversity of Michigan
Martha Sajatovic, MD*Case Western Reserve University School of Medicine
Consultant: Neurocrine Disclosure Policy
It is the policy of the American Epilepsy Society (AES) to ensure balance, independence, objectivity and scientific rigor. All individuals involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. Conflicts of interest will be resolved by AES prior to an educational activity being delivered to learners.
Planning Committee, Faculty, Reviewers' Disclosures of Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, the AES requires that any person who is in a position to control content of a CME activity must disclose all relevant financial relationships that they have with an ineligible company. Unless otherwise indicated (*), none of the planners or faculty of this activity have any financial relationships to disclose. All relevant financial relationships with
ineligible companies have been mitigated. The following individuals contributed to this activity’s content. Update for all courses this year.
Planners and Faculty
Elaine T. Kiriakopoulos, MD, MPH, MSc
Geisel School of Medicine, Dartmouth College
Barbara Jobst, MD, Dr. Med, FAES, FAAN*Geisel School of Medicine, Dartmouth College
Contract Research: Neuropace, Inc.Carly R. Sykes, MPHDepartment of Neurology, Dartmouth Health
Andrea Bernasconi, MDMcConnell Brain Imaging Centre
Jorge Burneo, MD, MPH, FAAN, FAES*Western University
Grant: Sunovion Canada, EisaiKelly Conner, PhD, MMSc, MS, PA-C*Wake Forest School of Medicine
Consultant: Neurelis, SK Life Science, Inc.Chris Dulla, PhDTufts University School of Medicine
Elizabeth Felton, MD, PhDUW Health
Alicia Goldman, MD, PhD, FAESBaylor College of Medicine
Zachary Grinspan, MD, FAESWeill Cornell Medical College
Shanna Guilfoyle, PhD, FAESCincinnati Children's Hospital Medical Center
Robert E. Hogan, MD, FAAN, FAES* Washington University in St. LouisContractor: Biogen, Inc., Otsuka Pharmaceutical, Cerevel Therapeutics, Engage Therapeutics, Neurelis Inc.; Consultant: Neurelis Inc.Kelly Knupp, MD, FAES* University of ColoradoConsultant: Zogenix, Biodex, Epygenix; Contractor: GW Pharmaceuticals, EpygenixSuzette LaRoche, MD, FAESUniversity of North Carolina
Judy Liu, MD, PhDBrown University
Joaquin Lugo, PhD, FAESBaylor University
Jamie Maguire, PhDTufts University School of Medicine
Mohamad Mikati, MD, FAESDuke University Medical Center
Dean Naritoku, MD, FAES* University of South AlabamaConsultant: SK Life; Contractor: Eisai, Inc., SK Life, Sunovion Pharmaceuticals Inc.
Madonna Plueger, MSN, APRN, ACNS-BC
Barrow Neurological Institute
Kinshuk Sahaya, MD, FAES
Minnesota Epilepsy Group
Sarah Schmitt, MD, FAES
Medical University of South Carolina
Elaine Seto, MD, PhD
Baylor College of Medicine
Ignacio Valencia, MD, FAES*
St. Christopher's Hospital for Children
Contract Research (PI): UCB SA
Daniel Weber, DO, FAES*
St. Louis University
Consultant: SK Life Science Inc; Neurocrine Biosciences, Inc.
CME Reviewer
Kan Ding
Ifrah Zawar
Subhendu Rath
Rebecca SpiegelAmerican Epilepsy Society Staff Planners
Alexis Griffith, MPH American Epilepsy Society
Shawna Strickland, PhD, CAE, RRT, FAARC American Epilepsy Society
Anne Gramiak, MPH, MSLOC American Epilepsy Society
Cristina Graham, BS American Epilepsy Society
Melissa Ball, MS, CAE, PMP American Epilepsy Society
Resolution of Conflicts of Interest
It is the policy of the American Epilepsy Society to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. In accordance with the ACCME Standards of Integrity and Independence in Accredited Continuing Education, the AES implemented the mechanisms of prospective peer review of this CME activity, to identify and resolve any conflicts. Additionally, the content of this activity is based on the best available evidence.
AccreditationThe American Epilepsy Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
For more information regarding contact hours, please call American Epilepsy Society 312.883.3800 or
education@aesnet.org.
Credit DesignationThe American Epilepsy Society designates this enduring activity for a maximum of 3.0
AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME CertificateTo receive credit for your participation in this activity, please complete the evaluation survey provided at the conclusion of the activity.
Unapproved Use DisclosureThe American Epilepsy Society requires CME authors to disclose to learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Information about pharmaceutical agents/devices that is outside of U.S. Food and Drug Administration approved labeling may be contained in this activity.
DisclaimerThis CME activity is for educational purposes only and does not constitute the opinion or endorsement of, or promotion by, the American Epilepsy Society. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label, investigational and/or experimental uses.